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not only alter TGRL concentration and composition, but also affect LDL, HDL, and inflammatory pathways.
This state-of-the-art review discusses the complexities of TGRL-associated atherosclerotic CVD risk and new directions in risk assessment and therapeutic responses to TG-lowering therapies from genetic studies.
It is not intended to reiterate recent consensus statements on hypertriglyceridemia definitions, diagnosis, and management (4, 5) .
TGRL, HUMAN ATHEROSCLEROSIS, AND ATHEROSCLEROTIC CARDIOVASCULAR EVENTS
Chylomicron and very low-density lipoprotein (VLDL) remnants rapidly penetrate the arterial wall and contribute cholesterol to atherosclerotic lesions (6) (7) (8) . VLDL composition is a critical CVD risk determinant. In retrospective and prospective population studies, TG-associated CHD risk was limited to apolipoprotein (Apo) C3-containing VLDL particles and their metabolic remnants, small LDL particles (9) (10) (11) . VLDL proteome analysis expanded the complexities of VLDL through identification of 33 functional pathways, including 4 related to lipid transport and lipoprotein metabolism, and 8 associated with coagulation, hemostasis, and immunity (12) .
METABOLISM OF INTESTINAL AND HEPATIC-DERIVED TGRLS
Chylomicrons are intestinal-specific lipoproteins, formed mainly in the jejunum after a meal. Owing to the large TG core (>90%), chylomicron density is <1.006 g/ml, but they are heterogeneous, ranging from 75 to 1,200 nm in diameter. They also contain a small amount of cholesteryl esters, 1 structural protein, apoB48, and minor exchangeable apolipoproteins.
Dietary TG are hydrolyzed in the stomach and proximal small intestine to form fatty acids and 2-monoacylglycerol (Central Illustration, top) (13) . (15) . Chylomicrons exit the ER to the Golgi via prechylomicron transport vesicles (16) . After a meal, chylomicrons are exported into mesenteric lymph before entering the circulation, where they contribute to post-prandial TG concentrations (17, 18) . Lipoprotein lipase (LPL) subsequently hydrolyzes chylomicrons into fatty acids used as an energy supply by the heart and skeletal muscles or stored in adipose tissue.
Enterocytes absorb these lipids through either passive
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Chylomicron remnants are removed from the circulation after binding to the LDL receptor via the apoE ligand, or by other routes including LDL receptorrelated protein 1 and the heparan sulfate proteoglycan pathway (19) . Although clearance is the primary mechanism for chylomicron remnants, ApoB48 overproduction increases chylomicron production in fructose-fed, insulin-resistant hamsters (20) .
VLDL biogenesis occurs in hepatocytes by a 2-step process involving synthesis of partially lipidated apoB100 to form a primordial VLDL particle (through a process involving MTP), followed by TG addition to the primordial particle in the ER lumen (Central Illustration, bottom). However, apoC3 inhibits VLDL assembly independent of MTP (21) . After assembly, nascent VLDL particles are transported to the Golgi by a rate-limiting step mediated by a specific ER-derived VLDL transport vesicle (22) . Cell death-inducing DFF45-like effector b (cideB) is a VTF-associated protein that mediates VLDL lipidation and maturation (23) . CideB silencing results in hepatic secretion of small VLDL particles, which is evidence that VLDL heterogeneity is, in part, genetically regulated.
LPL is the principal enzyme that hydrolyzes TG in TGRLs. LPL is primarily synthesized in the parenchyma of tissues that use fatty acids for energy (cardiac muscle, skeletal muscle) and TG storage (adipose tissue). LPL attaches to heparan sulfide side chains of proteoglycans, and is transported to the capillary lumen by the endothelial protein glycosylphosphatidylinositolanchored high-density lipoprotein-binding protein-1 (GPIHBP1) (24) . GPIHBP1 provides a platform for LPL to process TG from TGRL. TGRL hydrolysis at the capillary lumen releases free fatty acids and monoglycerides, resulting in partially catabolized chylomicrons (chylomicron remnants) and VLDL particles (VLDL remnants).
Due to its critical role in lipid homeostasis, LPL activity is highly regulated at the transcriptional, posttranscriptional, translational, and post-translational levels. Various proteins regulate LPL including: apoC1 (25, 26) , apoC2 (27) , apoC3 (26, 28) , apoA5 (29) , angiopoietin-like protein 3 (ANGPTL3) (30), ANGPTL4
(31,32), and ANGPTL8 (33) . ANGPTL4 is a secreted protein induced in adipose tissue by fasting (34) . TGRL binding stabilizes LPL; however, apoC1 and apoC3 displace LPL from LDs, where ANGPTL4 inactivates it in the subendothelial space. This allows ANGPTL4 to bind LPL's N-terminus, resulting in dissociation of catalytically active LPL homodimers to monomers (26) . ANGPTL3 renders LPL more susceptible to proteolytic inactivation by proprotein convertases (35) .
Low amounts of LPL are detected in human blood, where it is transported by both apoB48-and apoB100-containing lipoproteins. In humans, apoB-containing lipoproteins with LPL are cleared more rapidly than apoB-containing particles without LPL (36) . LPL was more effective in enhancing post-prandial clearance of apoB48-than apoB100-containing lipoproteins. Although apoE facilitates receptor-mediated TGRL clearance pathways, it did not affect TGRL clearance in this study.
The very low-density lipoprotein receptor (VLDLR), an LDL receptor family member (37) , is expressed in heart, skeletal muscle, and adipose tissue (38, 39) . Under most circumstances, it is not detected in the liver; however, fenofibrate activation of the peroxisome proliferatoractivated receptor (PPAR) alpha increases hepatic VLDLR translational activity through peroxisome proliferator response element binding to the VLDL promoter (40) .
After VLDLs bind to VLDLR, VLDL-derived FA are delivered to peripheral tissues, where they are used by heart and muscle for energy and in adipose tissue as an FA storage reservoir. ApoC3 impairs VLDL binding to cellular receptors, resulting in formation of small LDL particles (10, 11) , thereby counteracting the effects of apoE (41) .
INFLAMMATION
TGRLs produced from both the exogenous (chylomicrons) or endogenous (VLDL) pathways are Rosenson et al.
Triglyceride-Rich Lipoproteins and Atherosclerosis Rosenson et al. More recently, a Mendelian randomization study supports a causative role for remnant cholesterol in CHD (72) ( Table 2 ). In this study, a small number of The superiority of non-HDL-C as a biomarker of risk was suggested to not result from TGRL atherogenicity, but to instead reflect the relationship between non-HDL-C and the number of circulating LDL particles (84) . The basis for this argument is that whether or not an individual has hypertriglyceridemia, approximately 90% of apoB is found in LDL particles. In those with an elevated TG concentration, the average LDL particle size is typically smaller, and thus the LDL particle concentration is often higher than would be predicted from the LDL-C level. In the ARIC (Atherosclerosis Risk in Communities) study, small, dense LDL-C was associated with incident CHD (85) . In a GWAS performed in the ARIC study, the PCSK7 locus was associated with small, dense LDL-C, suggesting that genetic variants contribute to CHD risk. However, in a prospective study that adjusted for the risk of small LDL versus large LDL particles per total LDL particle concentration, risk relationships for incident CVD were not significantly higher for small LDL particles (86) .
In studies including higher proportions of individuals with insulin resistance (obesity, metabolic syndrome, and type 2 diabetes), the discordance between LDL-C and total and small LDL particles increases. After multivariate adjustment, including major CHD risk factors, TG, and HDL-C, LDL particles are associated with a 2-fold higher risk of atherosclerosis and CVD events (reviewed in Rosenson et al. [87] ).
These prospective studies were the basis for multiple professional society recommendations for a hierarchical approach emphasizing LDL-C, non-HDL-C, and apoB/LDL particles for evaluation of CVD risk (88) (89) (90) (91) .
Controversy exists regarding whether there is
an atherogenicity gradient across apoB-containing lipoproteins and, if so, whether it is incremental, particularly in the general population or in subpopulations with low insulin resistance rates (80) .
Most dyslipidemia guidelines recognize LDL-C as the major atherogenic lipoprotein and the primary target Since apoB is the major apolipoprotein of both LDL and VLDL, some investigators propose total apoB as an alternative to non-HDL-C (95).
TGRLS: LESSONS FROM HUMAN GENETICS
Over the past 15 years, human genetic studies have Rosenson et al. better tolerated, but is more hepatotoxic than 
